Table 1.
Baseline characteristics stratified by survival status
| Characteristic | All patients (n = 256) |
|||
|---|---|---|---|---|
| Non-2-year survivors (n = 194) |
2-year survivors (n = 62) |
P value | ||
| Sex | 0.7417 | |||
| Male | 202 (78.9) | 154 (79.4) | 48 (77.4) | |
| Female | 54 (21.1) | 40 (20.6) | 14 (22.6) | |
| Age*, years, median (range) | 66 (20–84) | 65 (20–84) | 67 (33–79) | 0.0227 |
| Age category | ||||
| < 65 years | 114 (44.5) | 94 (48.5) | 20 (32.3) | |
| ≥ 65 and < 75 years | 118 (46.1) | 79 (40.7) | 39 (62.9) | |
| ≥ 75 years | 24 (9.4) | 21 (10.8) | 3 (4.8) | |
| ECOG PS* | 0.0001 | |||
| 0 | 118 (46.1) | 78 (40.2) | 40 (64.5) | |
| 1 | 97 (37.9) | 77 (39.7) | 20 (32.3) | |
| ≥ 2 | 31 (12.1) | 31 (16.0) | 0 (0.0) | |
| Unknown | 10 (3.9) | 8 (4.1) | 2 (3.2) | |
| Primary site | ||||
| Hypopharynx | 64 (25.0) | 50 (25.8) | 14 (22.6) | 0.6133 |
| Oral cavity | 56 (21.9) | 44 (22.7) | 12 (19.4) | 0.5814 |
| Oropharynx | 40 (15.6) | 30 (15.5) | 10 (16.1) | 0.9001 |
| Salivary gland | 23 (9.0) | 17 (8.8) | 6 (9.7) | 0.8265 |
| Larynx | 21 (8.2) | 17 (8.8) | 4 (6.5) | 0.5637 |
| Maxillary sinus | 14 (5.5) | 11 (5.7) | 3 (4.8) | 0.8021 |
| Nasopharynx | 19 (7.4) | 11 (5.7) | 8 (12.9) | 0.0586 |
| Others | 19 (7.4) | 14 (7.2) | 5 (8.1) | 0.8245 |
| Previous treatment | ||||
| Surgery | 176 (68.8) | 132 (68.0) | 44 (71.0) | 0.6652 |
| Cetuximab | 155 (60.5) | 124 (63.9) | 31 (50.0) | 0.0510 |
| Chemoradiation therapy | 144 (56.3) | 107 (55.2) | 37 (59.7) | 0.5320 |
| Radiation therapy | 94 (36.7) | 74 (38.1) | 20 (32.3) | 0.4026 |
*Significant differences were observed between non-2-year survivors and 2-year survivors
Data are n (%) unless specified otherwise
ECOG PS Eastern Cooperative Oncology Group performance status